Similar Items: Longitudinal changes in DTI‐ALPS and choroid plexus volume relative to CSF biomarkers during lecanemab treatment in mild cognitive impairment: A pilot study
- Glymphatic clearance as revealed by diffusion tensor imaging along the perivascular space (DTI‐ALPS) is associated with Alzheimer's disease neuropathology and periodic rsEEG alpha rhythms in mild cognitive impairment participants
- Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging
- Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
- CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design
- Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment
- A potential multimodal biomarker – cognitive signature associated with the conversion from subjective cognitive decline to mild cognitive impairment